Value through Innovation16 April 2014

Exciting future - Increasing importance of China

The economic, demographic and lifestyle changes in the oncoming years will further increase the importance of emerging markets as key geographies with high need for medical treatments.

In these countries, acute diseases still account for a high burden of disease, but due to increasing wealth and changes in lifestyle, the population in the emerging markets is ageing and increasingly suffering from chronic diseases.
Growing disposable income, combined with investment in public health provision, in some countries, e. g. Brazil, China, Russia and Turkey, is raising healthcare standards and, concomitantly, increasing the use of drugs.

Special focus
Boehringer Ingelheim is reinforcing its engagement in the emerging markets in order to participate in their highly promising development. As the company’s pharmaceutical products meet the needs of the people in these economies, Boehringer Ingelheim plans to maintain the successful growth it has achieved in these markets in recent years. Key to its future engagement in emerging markets are the so-called BRIC countries (Brazil, Russia, India, China), with special focus currently on China.

Boehringer Ingelheim China is playing an increasingly important role for Human Pharmaceuticals as well as for the Animal Health business. The company’s business in China is primarily in Prescription Medicines, Consumer Health Care, Animal Health and Operations.

It is investing significantly in order to upgrade marketing and production capabilities in China, with a view to it being one of Boehringer Ingelheim’s major operating units in the years to come.

In brief

Boehringer Ingelheim China Founded in 1994
Number of employees 2010: 2,055 employees
Biggest products RX: Mucosolvan® ampules, Micardis®, Spiriva®, Sifrol®;
CHC: Mucosolvan® orals;
Animal Health:
Ingelvac series, Ingelvac CircoFLEX®,Enterisol ileitis
Boehringer Ingelheim’s share of the Chinese pharmaceutical market approx. 0,4 %
Zhangjiang Manufacturing plant in Shanghai 210 people currently working at Zhangjiang Plant.
products produced:
- solid formulas including tablet and capsules
- oral liquids
- packaging of ampoules
Investments foreseen Investment in plant expansion and Chemical Competence Center set-up
R&D + M 33 international and national studies conducted or planned in 2011.
Therapeutic areas: metabolic diseases, oncology CNS, cardiovascular disease, respiratory disease, etc.